Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ALOG's Cash to Debt is ranked higher than
96% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.66 vs. ALOG: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ALOG' s Cash to Debt Range Over the Past 10 Years
Min: 1.29  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.82
ALOG's Equity to Asset is ranked higher than
81% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. ALOG: 0.82 )
Ranked among companies with meaningful Equity to Asset only.
ALOG' s Equity to Asset Range Over the Past 10 Years
Min: 0.71  Med: 0.83 Max: 0.88
Current: 0.82
0.71
0.88
Interest Coverage No Debt
ALOG's Interest Coverage is ranked higher than
94% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 46.72 vs. ALOG: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ALOG' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 5
Z-Score: 7.54
M-Score: -2.62
WACC vs ROIC
7.32%
5.88%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 5.06
ALOG's Operating margin (%) is ranked higher than
61% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.26 vs. ALOG: 5.06 )
Ranked among companies with meaningful Operating margin (%) only.
ALOG' s Operating margin (%) Range Over the Past 10 Years
Min: -1.49  Med: 5.38 Max: 8.24
Current: 5.06
-1.49
8.24
Net-margin (%) 3.46
ALOG's Net-margin (%) is ranked higher than
61% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.99 vs. ALOG: 3.46 )
Ranked among companies with meaningful Net-margin (%) only.
ALOG' s Net-margin (%) Range Over the Past 10 Years
Min: 0.94  Med: 5.67 Max: 8.34
Current: 3.46
0.94
8.34
ROE (%) 3.51
ALOG's ROE (%) is ranked higher than
57% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.45 vs. ALOG: 3.51 )
Ranked among companies with meaningful ROE (%) only.
ALOG' s ROE (%) Range Over the Past 10 Years
Min: 0.9  Med: 5.88 Max: 9.9
Current: 3.51
0.9
9.9
ROA (%) 2.95
ALOG's ROA (%) is ranked higher than
63% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.96 vs. ALOG: 2.95 )
Ranked among companies with meaningful ROA (%) only.
ALOG' s ROA (%) Range Over the Past 10 Years
Min: 0.76  Med: 4.97 Max: 7.98
Current: 2.95
0.76
7.98
ROC (Joel Greenblatt) (%) 9.02
ALOG's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -13.49 vs. ALOG: 9.02 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ALOG' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2.21  Med: 11.09 Max: 18.74
Current: 9.02
-2.21
18.74
Revenue Growth (3Y)(%) 1.40
ALOG's Revenue Growth (3Y)(%) is ranked lower than
58% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.40 vs. ALOG: 1.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ALOG' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.4  Med: 5.30 Max: 15.9
Current: 1.4
-10.4
15.9
EBITDA Growth (3Y)(%) 3.40
ALOG's EBITDA Growth (3Y)(%) is ranked higher than
53% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.80 vs. ALOG: 3.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ALOG' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -41.1  Med: 0.70 Max: 62.7
Current: 3.4
-41.1
62.7
EPS Growth (3Y)(%) -8.10
ALOG's EPS Growth (3Y)(%) is ranked lower than
63% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.60 vs. ALOG: -8.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ALOG' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -56  Med: -4.70 Max: 128.8
Current: -8.1
-56
128.8
» ALOG's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-06-04)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

ALOG Guru Trades in Q1 2015

Richard Snow 80,345 sh (+35.42%)
NWQ Managers 530,517 sh (+12.60%)
Chuck Royce 576,495 sh (+4.84%)
Jim Simons Sold Out
Paul Tudor Jones 3,600 sh (-42.03%)
» More
Q2 2015

ALOG Guru Trades in Q2 2015

Paul Tudor Jones 8,700 sh (+141.67%)
Richard Snow 136,390 sh (+69.76%)
NWQ Managers 552,722 sh (+4.19%)
Chuck Royce 539,395 sh (-6.44%)
» More
Q3 2015

ALOG Guru Trades in Q3 2015

Mariko Gordon 531,690 sh (New)
Jim Simons 9,554 sh (New)
Richard Snow 158,244 sh (+16.02%)
Chuck Royce 541,645 sh (+0.42%)
Paul Tudor Jones Sold Out
NWQ Managers 480,742 sh (-13.02%)
» More
Q4 2015

ALOG Guru Trades in Q4 2015

Jim Simons 21,754 sh (+127.70%)
Richard Snow 184,779 sh (+16.77%)
NWQ Managers 508,722 sh (+5.82%)
Mariko Gordon 557,904 sh (+4.93%)
Chuck Royce 542,745 sh (+0.20%)
» More
» Details

Insider Trades

Latest Guru Trades with ALOG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Analogic Corp

Mariko Gordon Uses Her Magic Touch and Acquires Holdings in 2 Companies Guru buys 3,356,338 shares of Babcock & Wilcox Enterprises and Analogic Corp.
Mariko Gordon (Trades, Portfolio), CFA, founder, CEO and CIO of Daruma Capital Management, has bought 2,824,648 shares of Babcock & Wilcox Enterprises Inc. (NYSE:BW) and 531,690 shares of Analogic Corp. (NASDAQ:ALOG) . Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 55.14
ALOG's P/E(ttm) is ranked lower than
83% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 28.31 vs. ALOG: 55.14 )
Ranked among companies with meaningful P/E(ttm) only.
ALOG' s P/E(ttm) Range Over the Past 10 Years
Min: 10.78  Med: 32.17 Max: 150.52
Current: 55.14
10.78
150.52
Forward P/E 16.21
ALOG's Forward P/E is ranked higher than
76% of the 42 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.92 vs. ALOG: 16.21 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 55.14
ALOG's PE(NRI) is ranked lower than
83% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.12 vs. ALOG: 55.14 )
Ranked among companies with meaningful PE(NRI) only.
ALOG' s PE(NRI) Range Over the Past 10 Years
Min: 15.03  Med: 33.10 Max: 172.94
Current: 55.14
15.03
172.94
Price/Owner Earnings (ttm) 53.02
ALOG's Price/Owner Earnings (ttm) is ranked lower than
79% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 33.08 vs. ALOG: 53.02 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ALOG' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 10.97  Med: 36.48 Max: 485.21
Current: 53.02
10.97
485.21
P/B 1.93
ALOG's P/B is ranked higher than
74% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.03 vs. ALOG: 1.93 )
Ranked among companies with meaningful P/B only.
ALOG' s P/B Range Over the Past 10 Years
Min: 0.82  Med: 1.79 Max: 2.53
Current: 1.93
0.82
2.53
P/S 1.92
ALOG's P/S is ranked higher than
70% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. ALOG: 1.92 )
Ranked among companies with meaningful P/S only.
ALOG' s P/S Range Over the Past 10 Years
Min: 0.78  Med: 1.80 Max: 3.09
Current: 1.92
0.78
3.09
PFCF 35.16
ALOG's PFCF is ranked lower than
58% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.30 vs. ALOG: 35.16 )
Ranked among companies with meaningful PFCF only.
ALOG' s PFCF Range Over the Past 10 Years
Min: 13.87  Med: 33.77 Max: 169.1
Current: 35.16
13.87
169.1
POCF 26.30
ALOG's POCF is ranked lower than
70% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.11 vs. ALOG: 26.30 )
Ranked among companies with meaningful POCF only.
ALOG' s POCF Range Over the Past 10 Years
Min: 9.02  Med: 21.68 Max: 81.55
Current: 26.3
9.02
81.55
EV-to-EBIT 32.60
ALOG's EV-to-EBIT is ranked lower than
73% of the 98 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.72 vs. ALOG: 32.60 )
Ranked among companies with meaningful EV-to-EBIT only.
ALOG' s EV-to-EBIT Range Over the Past 10 Years
Min: -121.6  Med: 24.95 Max: 388.6
Current: 32.6
-121.6
388.6
EV-to-EBITDA 17.46
ALOG's EV-to-EBITDA is ranked lower than
63% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 13.76 vs. ALOG: 17.46 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALOG' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.9  Med: 15.20 Max: 48.4
Current: 17.46
5.9
48.4
PEG 5.14
ALOG's PEG is ranked lower than
84% of the 38 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.57 vs. ALOG: 5.14 )
Ranked among companies with meaningful PEG only.
ALOG' s PEG Range Over the Past 10 Years
Min: 0.8  Med: 2.09 Max: 345.88
Current: 5.14
0.8
345.88
Shiller P/E 45.03
ALOG's Shiller P/E is ranked lower than
57% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.90 vs. ALOG: 45.03 )
Ranked among companies with meaningful Shiller P/E only.
ALOG' s Shiller P/E Range Over the Past 10 Years
Min: 15.43  Med: 34.64 Max: 53.68
Current: 45.03
15.43
53.68
Current Ratio 4.39
ALOG's Current Ratio is ranked higher than
71% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.78 vs. ALOG: 4.39 )
Ranked among companies with meaningful Current Ratio only.
ALOG' s Current Ratio Range Over the Past 10 Years
Min: 2.82  Med: 5.13 Max: 7.99
Current: 4.39
2.82
7.99
Quick Ratio 2.71
ALOG's Quick Ratio is ranked higher than
55% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. ALOG: 2.71 )
Ranked among companies with meaningful Quick Ratio only.
ALOG' s Quick Ratio Range Over the Past 10 Years
Min: 2.13  Med: 3.81 Max: 6.15
Current: 2.71
2.13
6.15
Days Inventory 171.41
ALOG's Days Inventory is ranked lower than
79% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 94.76 vs. ALOG: 171.41 )
Ranked among companies with meaningful Days Inventory only.
ALOG' s Days Inventory Range Over the Past 10 Years
Min: 92.53  Med: 114.57 Max: 151.19
Current: 171.41
92.53
151.19
Days Sales Outstanding 65.48
ALOG's Days Sales Outstanding is ranked higher than
50% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.42 vs. ALOG: 65.48 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALOG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 54.12  Med: 66.61 Max: 80.6
Current: 65.48
54.12
80.6
Days Payable 36.50
ALOG's Days Payable is ranked lower than
67% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 54.01 vs. ALOG: 36.50 )
Ranked among companies with meaningful Days Payable only.
ALOG' s Days Payable Range Over the Past 10 Years
Min: 27.53  Med: 35.65 Max: 45.64
Current: 36.5
27.53
45.64

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.50
ALOG's Dividend Yield is ranked lower than
81% of the 75 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.38 vs. ALOG: 0.50 )
Ranked among companies with meaningful Dividend Yield only.
ALOG' s Dividend Yield Range Over the Past 10 Years
Min: 0.41  Med: 0.63 Max: 1.6
Current: 0.5
0.41
1.6
Dividend Payout 0.27
ALOG's Dividend Payout is ranked higher than
91% of the 47 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.34 vs. ALOG: 0.27 )
Ranked among companies with meaningful Dividend Payout only.
ALOG' s Dividend Payout Range Over the Past 10 Years
Min: 0.04  Med: 0.19 Max: 5
Current: 0.27
0.04
5
Forward Dividend Yield 0.50
ALOG's Forward Dividend Yield is ranked lower than
85% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.35 vs. ALOG: 0.50 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 0.50
ALOG's Yield on cost (5-Year) is ranked lower than
85% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.67 vs. ALOG: 0.50 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ALOG' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.41  Med: 0.63 Max: 1.6
Current: 0.5
0.41
1.6
3-Year Average Share Buyback Ratio -0.10
ALOG's 3-Year Average Share Buyback Ratio is ranked higher than
85% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.30 vs. ALOG: -0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALOG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1.3  Med: -0.50 Max: 3.2
Current: -0.1
-1.3
3.2

Valuation & Return

vs
industry
vs
history
Price/Net Cash 159.98
ALOG's Price/Net Cash is ranked lower than
99% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.50 vs. ALOG: 159.98 )
Ranked among companies with meaningful Price/Net Cash only.
ALOG' s Price/Net Cash Range Over the Past 10 Years
Min: 3.17  Med: 7.81 Max: 148.14
Current: 159.98
3.17
148.14
Price/Net Current Asset Value 3.60
ALOG's Price/Net Current Asset Value is ranked higher than
75% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.07 vs. ALOG: 3.60 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ALOG' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.28  Med: 2.56 Max: 4.77
Current: 3.6
1.28
4.77
Price/Tangible Book 2.50
ALOG's Price/Tangible Book is ranked higher than
72% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.31 vs. ALOG: 2.50 )
Ranked among companies with meaningful Price/Tangible Book only.
ALOG' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.93  Med: 1.90 Max: 3.17
Current: 2.5
0.93
3.17
Price/Projected FCF 1.51
ALOG's Price/Projected FCF is ranked higher than
70% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.00 vs. ALOG: 1.51 )
Ranked among companies with meaningful Price/Projected FCF only.
ALOG' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.8  Med: 1.39 Max: 2.06
Current: 1.51
0.8
2.06
Price/Median PS Value 1.05
ALOG's Price/Median PS Value is ranked lower than
53% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.00 vs. ALOG: 1.05 )
Ranked among companies with meaningful Price/Median PS Value only.
ALOG' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.43  Med: 0.96 Max: 1.54
Current: 1.05
0.43
1.54
Price/Peter Lynch Fair Value 7.55
ALOG's Price/Peter Lynch Fair Value is ranked lower than
100% of the 25 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.07 vs. ALOG: 7.55 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ALOG' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.82  Med: 2.39 Max: 14.5
Current: 7.55
0.82
14.5
Price/Graham Number 2.47
ALOG's Price/Graham Number is ranked higher than
51% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.44 vs. ALOG: 2.47 )
Ranked among companies with meaningful Price/Graham Number only.
ALOG' s Price/Graham Number Range Over the Past 10 Years
Min: 1  Med: 1.63 Max: 11.2
Current: 2.47
1
11.2
Earnings Yield (Greenblatt) (%) 3.05
ALOG's Earnings Yield (Greenblatt) (%) is ranked higher than
63% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.30 vs. ALOG: 3.05 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ALOG' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.3  Med: 3.90 Max: 8.3
Current: 3.05
0.3
8.3
Forward Rate of Return (Yacktman) (%) 10.06
ALOG's Forward Rate of Return (Yacktman) (%) is ranked higher than
52% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.85 vs. ALOG: 10.06 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ALOG' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -20.7  Med: 4.50 Max: 33.9
Current: 10.06
-20.7
33.9

More Statistics

Revenue(Mil) $531
EPS $ 1.45
Beta0.73
Short Percentage of Float6.36%
52-Week Range $68.71 - 90.70
Shares Outstanding(Mil)12.42

Analyst Estimate

Jul16 Jul17 Jul18
Revenue(Mil) 518 550 587
EPS($) 3.42 4.94 5.98
EPS without NRI($) 3.42 4.94 5.98

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NAS:MYGN, SZSE:300463, TSE:4544, NAS:CPHD, NAS:NEOG, NAS:KANG » details
Traded in other countries:AJM.Germany,
Analogic Corporation was incorporated in the Commonwealth of Massachusetts in November 1967. The company is a technology company that designs and manufactures medical imaging and security systems and subsystems sold to original equipment manufacturers, or OEMs, and end users mainly in the healthcare and airport security markets. The Company's operating segments are Ultrasound, Medical Imaging, and Security and Detection. The Ultrasound segment provides ultrasound guidance systems for the urology and surgery markets and is expanding into point of care areas such as anesthesia and emergency medicine. The Medical Imaging segment provides critical enabling medical imaging systems and subsystems for computed tomography, or CT, magnetic resonance imaging, or MRI and high-resolution digital mammography systems. The Security and Detection segment designs and manufactures automated threat detection systems for aviation baggage inspection applications utilizing CT technology. Its geographical areas include United states, Japan, Germany, Netherlands and others.
» More Articles for ALOG

Headlines

Articles On GuruFocus.com
Mariko Gordon Sells Stake in Dealertrack Technologies Dec 02 2015 
Mariko Gordon Uses Her Magic Touch and Acquires Holdings in Two Companies Nov 23 2015 
Could These Science Stocks Provide Big Gains? Mar 11 2012 
Weekly Top Insider Buys: Health Care REIT Inc., Human Genome Sciences Inc., Conseco Inc., Universal Jan 02 2010 
Analogic Corp. Reports Operating Results (10-K) Sep 29 2009 
Analogic Corp. (ALOG) Files Quarterly Report for the Period Ended on 2008-10-31 Dec 15 2008 

More From Other Websites
ETF’s with exposure to Analogic Corp. : April 20, 2016 Apr 20 2016
Analogic to Present at the 15th Annual Needham Healthcare Conference Apr 05 2016
Analogic to Present at the 15th Annual Needham Healthcare Conference Apr 05 2016
Coverage initiated on Analogic by Sidoti Mar 24 2016
ETF’s with exposure to Analogic Corp. : March 22, 2016 Mar 22 2016
Analogic Corp. :ALOG-US: Earnings Analysis: Q2, 2016 By the Numbers Mar 18 2016
BK Ultrasound, Powered by Analogic, Introduces the bk3500 Ultrasound System Mar 17 2016
Analogic Corp. breached its 50 day moving average in a Bearish Manner : ALOG-US : March 17, 2016 Mar 17 2016
ANALOGIC CORP Financials Mar 09 2016
ANALOGIC CORP Files SEC form 10-Q, Quarterly Report Mar 03 2016
Analogic Corp. breached its 50 day moving average in a Bullish Manner : ALOG-US : March 3, 2016 Mar 03 2016
Edited Transcript of ALOG earnings conference call or presentation 2-Mar-16 10:00pm GMT Mar 03 2016
ANALOGIC CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 02 2016
Analogic reports 2Q loss Mar 02 2016
Analogic reports 2Q loss Mar 02 2016
Analogic Announces Results for the Second Quarter Ended January 31, 2016 and Declares Quarterly Cash... Mar 02 2016
Q2 2016 Analogic Corp Earnings Release - After Market Close Mar 02 2016
Analogic Announces Timing for Second Quarter Fiscal Year 2016 Earnings Conference Call and Webcast Feb 18 2016
BK Ultrasound, Powered by Analogic, Enters Dialysis Market With the First Commercial Order for Its... Feb 10 2016
Analogic Demonstrates Superior Detection and Higher Passenger Throughput With 3D CT Technology at... Feb 08 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK